Cardiovascular · Calcium Channel BlockerRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Verapamil Hydrochloride ANDA211035

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:31:51 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval status to Somerset for Verapamil Hydrochloride is significant as it may disrupt existing market dynamics and increase competition against branded products. Portfolio teams must evaluate the implications for market share and pricing strategies in the cardiovascular segment. Regulatory context from FDA (FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Verapamil products. The strongest clinical anchor is Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Calcium Channel Blocker, 8 regulatory and 2 competitive items passed relevance filtering for Somerset.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme. This approval may enhance Somerset's position in the cardiovascular market, potentially increasing competition against branded formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL) (FDA). Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda). The approval signifies a regulatory shift that could influence future applications and market entries, necessitating close monitoring of compliance and competitive responses.

Key Risks

Elevated medium regulatory exposure for Somerset could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Somerset through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Somerset's approval could lead to increased competition, potentially affecting revenue and market share for current Verapamil products. Companies may need to adjust pricing strategies to maintain competitiveness.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Verapamil products.

What Would Change This Assessment

This becomes more urgent if Monitor for market entry timelines and any potential challenges from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RILPIVIRINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Validate the Effect of Calcium Oral Spray on Early Childhood Caries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)

Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from Dutch societal perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Somerset
Verapamil Hydrochloride

Commercial impact

medium

Somerset's approval could lead to increased competition, potentially affecting revenue and market share for current Verapamil products. Companies may need to adjust pricing strategies to maintain competitiveness.

Regulatory impact

medium

The approval signifies a regulatory shift that could influence future applications and market entries, necessitating close monitoring of compliance and competitive responses.

What to watch

Monitor for market entry timelines and any potential challenges from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.